20 Yet despite this heightened need, Black patients are far less likely to be prescribed GLP-1 products
TRIUMPH-4 has not been published in a peer-reviewed journal
It is a triple receptor agonist meaning it activates three key hormone pathways that play a role in glucose metabolism and appetite regulation: Glucagon-like peptide-1 (GLP-1) receptor involved in insulin secretion, appetite suppression, and slowing digestion
These questions are not specific to altRx
Key Takeaways Retatrutide targets three hormones (GLP-1, GIP, glucagon), tirzepatide targets two (GLP-1, GIP), and semaglutide targets one (GLP-1) At 68 weeks, retatrutide achieved 28.7% average weight loss, tirzepatide approximately 22%, and semaglutide around 17% on the highest doses Side effects are similar across all three medications, mainly digestive issues like nausea and diarrhoea Retatrutide is not yet approved and won't be available until mid-2026 at the earliest Retatrutide is not yet approved and is not currently available in the UK Tirzepatide (Mounjaro) and semaglutide (Wegovy) are both available now in the UK through NHS or private providers By entering I agree to the Terms and Conditions
What happens after you stop taking retatrutide
